Manages acute pain severe enough to require an opioid analgesic. ANDA 201952, held by Micro Labs Ltd India. Acetaminophen; Tramadol Hydrochloride.
As of Nov 20, 2026, ANDA 201952 (Tramadol Hydrochloride and Acetaminophen), held by Micro Labs Ltd India, was first approved by FDA on Dec 14, 2012, with 14 approved supplements and 0 published complete response letters.
Tramadol hydrochloride and acetaminophen tablets are indicated for the management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Limitations of Use Tramadol hydrochloride and acetaminophen tablets are indicated for short-term use of five days or less. Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, reserve tramadol hydrochloride and acetaminophen for use in patients for whom alternative treatment options [e.g., non-opioid analgesics]: Have not been tolerated, or are not expected to be tolerated, Have not provided adequate analgesia, or are not expected to provide adequate analgesia.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 14, 2012 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Tramadol Hydrochloride and Acetaminophen325MG;37.5MG · tablet;oral | Acetaminophen; Tramadol Hydrochloride | Discontinued |
| Jun 18, 2026 | Supplement 18REMS | Approved | None posted |
| Dec 22, 2025 | Supplement 17Labeling · Standard review | Approved | None posted |
| Dec 12, 2025 | Supplement 15Labeling · Standard review | Approved | None posted |
| Oct 31, 2024 | Supplement 16REMS | Approved | None posted |
| Dec 15, 2023 | Supplement 14Labeling · Standard review | Approved | None posted |
| Aug 3, 2022 | Supplement 7Labeling · Standard review | Approved | None posted |
| Aug 3, 2022 | Supplement 8Labeling · Standard review | Approved | None posted |
| Aug 3, 2022 | Supplement 10Labeling · Standard review | Approved | None posted |
| Aug 3, 2022 | Supplement 11Labeling · Standard review | Approved | None posted |
| Aug 3, 2022 | Supplement 12Labeling · Standard review | Approved | None posted |
| Aug 3, 2022 | Supplement 13Labeling · Standard review | Approved | None posted |
| Sep 18, 2018 | Supplement 9REMS | Approved | None posted |
| Mar 23, 2017 | Supplement 6Labeling · Standard review | Approved | None posted |
| Aug 1, 2014 | Supplement 1Labeling · Standard review | Approved | None posted |
| Dec 14, 2012 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters